Chronic, recurrent Lymphocytic Leukemia Active Not Recruiting Phase 2 Trials for Ibrutinib (DB09053)
Also known as: Recurrent Chronic Lymphocytic Leukemia
| Indication | Status | Phase |
|---|---|---|
| DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia) | Active Not Recruiting | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT02756897 | Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | Treatment | |
| NCT02869633 | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | Treatment | |
| NCT02007044 | Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | Treatment | |
| NCT02420912 | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation | Treatment | |
| NCT03045328 | Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL | Treatment |